Source comparison
PT-141 Nasal vs Injectable: Delivery Method Comparison
Bioavailability 80–94% systemic absorption 25–40% systemic absorption Injectable delivers 2–3× more peptide to target receptors per milligram administered Onset Time 45–60 minutes to Cmax 90–120 minutes to Cmax Injectable achieves therapeutic plasma levels in
This comparison does not assign a generated winner or score.
- Bioavailability
- 80–94% systemic absorption
- 25–40% systemic absorption
- Injectable delivers 2–3× more peptide to target receptors per milligram administered
- Onset Time
- 45–60 minutes to Cmax
- 90–120 minutes to Cmax
- Injectable achieves therapeutic plasma levels in half the time required for nasal
- Dose Precision
- ±5% variability (syringe accuracy)
- ±30–40% variability (mucosal factors)
- Injectable dosing is reproducible; nasal absorption fluctuates significantly between sessions
- Administration Complexity
- Requires sterile technique, needle handling
- Single-step actuation, no preparation
- Nasal spray is simpler but sacrifices pharmacokinetic control
- Side Effect Profile
- Injection site reactions (10–15%), transient nausea (20–25%)
- Nasal congestion/irritation (30–35%), transient nausea (15–20%)
- Both routes produce melanocortin-mediated nausea; nasal adds local mucosal irritation
- Cost Per Effective Dose
- $15–25 per 1.75mg dose
- $25–40 per 3–4mg dose (adjusted for bioavailability)
- Injectable is more cost-efficient when normalised for delivered peptide
- The table underscores the trade-off: nasal spray sacrifices potency and consistency for convenience. In research settings where outcome measurement depends on consistent receptor activation, injectable PT-141 is the only defensible choice. For exploratory studies where ease of administration outweighs precision, nasal formulations remain viable. But dose adjustments upward of 50–100% are necessary to approximate injectable effects.